Sandra Lovell

2.2k total citations · 1 hit paper
26 papers, 1.2k citations indexed

About

Sandra Lovell is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Sandra Lovell has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hepatology, 16 papers in Epidemiology and 8 papers in Infectious Diseases. Recurrent topics in Sandra Lovell's work include Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (13 papers) and Hepatitis B Virus Studies (7 papers). Sandra Lovell is often cited by papers focused on Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (13 papers) and Hepatitis B Virus Studies (7 papers). Sandra Lovell collaborates with scholars based in United States, France and United Kingdom. Sandra Lovell's co-authors include Fred Poordad, Christophe Hézode, Kosh Agarwal, Andrew Campbell, Roger Trinh, Heiner Wedemeyer, Mitchell L. Shiffman, Thomas Berg, Stefan Zeuzem and Xavier Forns and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

Sandra Lovell

24 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

2014 646 citations Fred Poordad, Christophe Hézode et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Lovell United States	11	1.2k	998	346	72	39	26	1.2k
Kathryn Razavi‐Shearer United States	7	1.5k 1.3×	1.4k 1.4×	207 0.6×	72 1.0×	26 0.7×	14	1.7k
Mohamed Hassany Egypt	16	775 0.7×	778 0.8×	134 0.4×	54 0.8×	14 0.4×	95	1.0k
Stephen Pianko Australia	14	1.0k 0.9×	949 1.0×	150 0.4×	61 0.8×	41 1.1×	27	1.1k
S Zeuzem Germany	11	788 0.7×	740 0.7×	115 0.3×	84 1.2×	26 0.7×	42	933
Roger Trinh United States	13	1.0k 0.9×	886 0.9×	420 1.2×	48 0.7×	25 0.6×	38	1.2k
Giuseppe Cariti Italy	22	869 0.7×	804 0.8×	271 0.8×	60 0.8×	54 1.4×	82	1.1k
Franco Felizarta United States	15	982 0.8×	847 0.8×	691 2.0×	80 1.1×	32 0.8×	37	1.4k
Daniel E. Cohen United States	19	1.4k 1.2×	1.3k 1.3×	491 1.4×	111 1.5×	26 0.7×	55	1.6k
Guy De La Rosa United States	14	1.4k 1.2×	1.2k 1.3×	513 1.5×	124 1.7×	39 1.0×	36	1.7k
Natarajan Ravendhran United States	13	821 0.7×	767 0.8×	188 0.5×	86 1.2×	20 0.5×	30	923

Countries citing papers authored by Sandra Lovell

Since Specialization

Citations

This map shows the geographic impact of Sandra Lovell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Lovell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Lovell more than expected).

Fields of papers citing papers by Sandra Lovell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Lovell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Lovell. The network helps show where Sandra Lovell may publish in the future.

Co-authorship network of co-authors of Sandra Lovell

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Lovell. A scholar is included among the top collaborators of Sandra Lovell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Lovell. Sandra Lovell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Hong, Kevin J. Gleason, Yiran Hu, et al.. (2022). Handling death as an intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials. Contemporary Clinical Trials. 119. 106758–106758. 2 indexed citations

Zamor, Philippe J., Ashley Brown, Douglas E. Dylla, et al.. (2021). High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. The American Journal of Gastroenterology. 116(9). 1896–1904. 8 indexed citations

Jonas, Maureen M., Robert H. Squires, Susan Rhee, et al.. (2019). Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study. Hepatology. 71(2). 456–462. 68 indexed citations

Flamm, Steven L., K. Rajender Reddy, Neddie Zadeikis, et al.. (2018). Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. Clinical Gastroenterology and Hepatology. 17(3). 527–535.e6. 17 indexed citations

Puoti, Massimo, Graham R. Foster, Stanley Wang, et al.. (2018). High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of Hepatology. 69(2). 293–300. 112 indexed citations

Ng, Teresa I., Edward Tam, Rakesh Tripathi, et al.. (2018). Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses. 10(9). 462–462. 3 indexed citations

Gane, Edward, Kazuaki Chayama, Stuart K. Roberts, et al.. (2018). Mo1411 - An Integrated Analysis of the Efficacy of Glecaparevir/Pibrentasvir by Geographical Region. Gastroenterology. 154(6). S–1198. 1 indexed citations

Poordad, Fred, Franco Felizarta, Armen Asatryan, et al.. (2017). Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment. Hepatology. 66(2). 389–397. 137 indexed citations

Poordad, Fred, Franco Felizarta, Stanley Wang, et al.. (2016). 752 High SVR Rates With the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection. Gastroenterology. 150(4). S1046–S1047. 2 indexed citations

10.

Foster, Graham R., Edward Gane, Armen Asatryan, et al.. (2016). Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection. Journal of Hepatology. 64(2). S292–S292. 2 indexed citations

11.

Poordad, F., Franco Felizarta, Armen Asatryan, et al.. (2016). High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection. Journal of Hepatology. 64(2). S768–S768. 4 indexed citations

12.

Muir, Andrew J., Simone I. Strasser, Stephen D. Shafran, et al.. (2016). High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection. Journal of Hepatology. 64(2). S186–S186. 8 indexed citations

13.

Forns, Xavier, Fred Poordad, Marcos Pedrosa, et al.. (2015). Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver International. 35(11). 2358–2362. 13 indexed citations

14.

Lawitz, Eric, William O’Riordan, Armen Asatryan, et al.. (2015). Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Antimicrobial Agents and Chemotherapy. 60(3). 1546–1555. 40 indexed citations

15.

Wedemeyer, Heiner, Thomas Berg, Steven L. Flamm, et al.. (2015). P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis. Journal of Hepatology. 62. S637–S638. 6 indexed citations

16.

Flamm, Steven L., Edward Gane, Jean‐François Dufour, et al.. (2014). Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials. Hepatology. 60. 4 indexed citations

17.

Poordad, Fred, Christophe Hézode, Roger Trinh, et al.. (2014). ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. New England Journal of Medicine. 370(21). 1973–1982. 646 indexed citations breakdown →

18.

Hézode, Christophe, Patrick Marcellin, Stanislas Pol, et al.. (2014). Results From the Phase 2 PEARL-I Study: Interferon-Free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection. The American Journal of Gastroenterology. 109. S131–S131.

19.

Hézode, Christophe, Patrick Marcellin, Stanislas Pol, et al.. (2014). O58 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION. Journal of Hepatology. 60(1). S24–S24. 21 indexed citations

20.

Dugdale, A. E., et al.. (1982). Refeeding after acute gastroenteritis: a controlled study.. PubMed Central. 57(1). 76–8. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact